TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device

Dow Jones

09/23

TriSalus Life Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device.

Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year.

The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said.

The company will launch a limited market release of the device in the coming weeks.

"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures," Chief Executive Mary Szela said. "We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients."

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2669273451"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2669273451\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2669273451?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-23 04:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2669273451","market":"other","top_or_hot":-1,"title":"TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSI\">TriSalus Life</a> Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n</p>\n<p>\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n</p>\n<p>\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n</p>\n<p>\n  The company will launch a limited market release of the device in the coming weeks. \n</p>\n<p>\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>TriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTriSalus Life Sciences Gets FDA Clearance for Drug Delivery Device\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-23 04:55</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/TLSI\">TriSalus Life</a> Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n</p>\n<p>\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n</p>\n<p>\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n</p>\n<p>\n  The company will launch a limited market release of the device in the coming weeks. \n</p>\n<p>\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\" \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2669273451","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2669273451","pubTimestamp":1790110500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"TriSalus Life Sciences said it received Food and Drug Administration 510 clearance for a new pressure-enabled drug delivery device.Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year.The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said.The company will launch a limited market release of the device in the coming weeks.\"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LABU":"三倍做多标普生物-Direxion","BK4585":"ETF&股票定投概念","TLSI":"TriSalus Life Sciences Inc.","BK4139":"生物科技"},"translate_title":"TriSalus Life Sciences 的药物输送装置获得 FDA 批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LABU":1.5,"TLSI":0.9},"content_text":"TriSalus Life Sciences said it received Food and Drug Administration 510(k) clearance for a new pressure-enabled drug delivery device. \n\n\n  Shares surged 26% to $6.21 on the news after Tuesday's closing bell. The stock closed down 1% at $4.93 and is down 29% this year. \n\n\n  The oncology company said the FDA greenlit TriNav Advance, the latest addition to the company's PEDD portfolio. The new device has access to small, distal vessels using a microcatheter and completes the company's portfolio addressing liver-directed therapy cases, TriSalus said. \n\n\n  The company will launch a limited market release of the device in the coming weeks. \n\n\n  \"TriNav Advance enhances our Pressure-Enabled Drug Delivery portfolio in support of the full range of liver embolization procedures,\" Chief Executive Mary Szela said. \"We are proud of the range of tools we offer to physicians and believe TriNav Advance will catalyze further adoption across these procedures. We're excited to broaden our portfolio in a way that can meaningfully benefit both physicians and patients.\"","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}